Clobazam Pharmacokinetics and Therapeutic Applications in Epilepsy

Clobazam is a 1,5‐benzodiazepine widely used as adjunctive therapy for a range of epileptic disorders, including Lennox–Gastaut syndrome, refractory focal and generalised seizures, and status epilepticus. Following oral administration, clobazam is absorbed rapidly, reaching peak plasma concentrations within one to four hours. It is extensively metabolised in the liver, primarily by CYP2C19, to form N-desmethylclobazam, which has similar anticonvulsant activity and a longer half-life. Both parent drug and metabolite distribute into the central nervous system, where they exert anticonvulsant effects via positive allosteric modulation of GABAA receptors, with a preferential affinity for subunits linked to anticonvulsant efficacy over sedation. The elimination half-life of clobazam ranges from 18 to 50 hours, while that of its metabolite can exceed 70 hours, leading to steady‐state concentrations after several days of dosing. Interindividual variability in CYP2C19 activity may necessitate dose adjustments or therapeutic drug monitoring in paediatric, elderly or organ-impaired populations. Clinically, clobazam is valued for its favourable safety profile, reduced sedative burden compared with classic benzodiazepines, and flexible formulations including tablets and oral suspension. Its global approval in over 100 countries attests to its broad therapeutic relevance, particularly in treatment-resistant epilepsy where combination regimens often incorporate clobazam to maximise seizure control while preserving quality of life.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Clobazam Pharmacokinetics and Therapeutic Applications in Epilepsy publication trend

The graph below shows the total number of articles in clobazam pharmacokinetics and therapeutic applications in epilepsy across all publications each year (not limited to Nature Index journals).

Technical terms

Pharmacokinetics: study of a drug’s absorption, distribution, metabolism and excretion.

CYP2C19: cytochrome P450 enzyme responsible for converting clobazam into its active metabolite.

Allosteric modulation: enhancement of receptor activity via binding at a site distinct from the agonist binding domain.

N-desmethylclobazam: principal active metabolite of clobazam with sustained anticonvulsant action.

Therapeutic drug monitoring: measurement of drug and metabolite concentrations to guide personalised dosing.

References

1. Effectiveness of Antiseizure Medication Triple Therapy in Patients With Glioma With Refractory Epilepsy. Neurology (2023).
2. Clobazam and its use in epilepsy. Pediatric Reports (2016).
3. Clobazam and Its Active Metabolite N-desmethylclobazam Display Significantly Greater Affinities for α2- versus α1-GABAA–Receptor Complexes. PLOS ONE (2014).
4. Clobazam as an adjunctive therapy in treating seizures associated with Lennox–Gastaut syndrome. Neuropsychiatric Disease and Treatment (2011).
5. Effects of clobazam for treatment of refractory status epilepticus. BMC Neurology (2016).
6. Determination of Clobazam and Its Major Metabolite N-desmethylclobazam in Human Plasma with High-Performance Liquid Chromatography. Analytica—A Journal of Analytical Chemistry and Chemical Analysis (2021).
7. A RARE ADVERSE EFFECT OF CLOBAZAM INDUCED RASH IN A CHILD WITH FIRES (FEBRILE INFECTION WITH REFRACTORY EPILEPSY SYNDROME). Asian Journal of Pharmaceutical and Clinical Research (2024).